Avant Technologies, Inc. Issues Retraction of September 24, 2025 Press Release
Avant Technologies (OTCQB: AVAI) has issued a retraction of its September 24, 2025 press release regarding a purported Joint Venture and License Agreement with Art-Islets Pte. Ltd. and Austrianova. The company clarified that no binding agreement has been executed between the parties at this time.
The company acknowledged that the previous announcement contained statements issued in error and emphasized that any descriptions of collaborative activities, technology contributions, or anticipated clinical development milestones from the retracted release should not be relied upon. Avant Technologies expressed regret for any confusion caused and reaffirmed its commitment to providing accurate information to stakeholders.
Avant Technologies (OTCQB: AVAI) ha emesso una rettifica relativa al comunicato stampa del 24 settembre 2025 riguardante una presunta joint venture e un accordo di licenza con Art-Islets Pte. Ltd. e Austrianova. L’azienda ha chiarito che nessun accordo vincolante è stato stipulato tra le parti al momento.
L’azienda riconosce che l’annuncio precedente conteneva affermazioni fornite per errore e ha sottolineato che qualsiasi descrizione di attività collaborative, contributi tecnologici o traguardi di sviluppo clinico previsti nella comunicazione ritirata non deve essere considerata affidabile. Avant Technologies ha espresso rammarico per qualsiasi confusione causata e ha ribadito il proprio impegno a fornire informazioni accurate agli stakeholder.
Avant Technologies (OTCQB: AVAI) ha emitido una retractación de su comunicado de prensa del 24 de septiembre de 2025 referente a una supuesta empresa conjunta y un acuerdo de licencia con Art-Islets Pte. Ltd. y Austrianova. La empresa aclaró que ningun acuerdo vinculante ha sido ejecutado entre las partes en este momento.
La compañía reconoció que el anuncio anterior contenía declaraciones emitidas por error y enfatizó que cualquier descripción de actividades de colaboración, aportes tecnológicos o hitos de desarrollo clínico anticipados en el comunicado retractado no debe hacerse confiar. Avant Technologies lamenta cualquier confusión causada y reafirma su compromiso de proporcionar información precisa a los interesados.
Avant Technologies (OTCQB: AVAI)가 Art-Islets Pte. Ltd. 및 Austrianova와의 추정 공동 사업 및 라이선스 계약에 관한 2025년 9월 24일 보도자료를 정정했다. 회사는 현재 양당 간에 구속력 있는 계약이 체결되지 않았다고 명확히 밝혔다.
회사는 이전 발표가 잘못된 진술을 포함하고 있었음을 인정했으며, 철회된 보도자료에서의 협력 활동 설명, 기술 기여 또는 임상 개발 이정표에 관한 기대 내용은 신뢰해서는 안 된다고 강조했다. Avant Technologies는 혼란을 야기한 점에 대해 유감을 표하며 이해관계자에게 정확한 정보를 제공하겠다는 약속을 재확인했다.
Avant Technologies (OTCQB: AVAI) a publié une correction concernant son communiqué de presse du 24 septembre 2025 relatif à une prétendue coentreprise et à un accord de licence avec Art-Islets Pte. Ltd. et Austrianova. La société a précisé qu'aucun accord contraignant n’a été conclu entre les parties à ce jour.
La société a reconnu que l’annonce précédente contenait des déclarations émises par erreur et a souligné que toute description des activités de collaboration, des contributions technologiques ou des jalons de développement clinique prévus dans le communiqué rétracté ne doit pas être considérée comme fiable. Avant Technologies a exprimé ses regrets pour la confusion causée et a réaffirmé son engagement à fournir des informations exactes aux parties prenantes.
Avant Technologies (OTCQB: AVAI) hat eine Berichtigung zu seiner Pressemitteilung vom 24. September 2025 bezüglich eines angeblichen Joint Ventures und eines Lizenzvertrags mit Art-Islets Pte. Ltd. und Austrianova veröffentlicht. Das Unternehmen stellte klar, dass zum jetzigen Zeitpunkt kein verbindliches Abkommen zwischen den Parteien zustande gekommen ist.
Das Unternehmen räumte ein, dass die frühere Ankündigung fehlerhafte Aussagen enthielt, und betonte, dass jegliche Beschreibungen von kooperativen Aktivitäten, technologischen Beiträgen oder erwarteten klinischen Entwicklungsmeilensteinen aus der zurückgerufenen Mitteilung nicht als verlässlich angesehen werden sollten. Avant Technologies bedauerte jegliche Verwirrung und bekräftigte sein Engagement, den Stakeholdern genaue Informationen zu liefern.
Avant Technologies (OTCQB: AVAI) أصدرت تصحيحاً بشأن بيانها الصحفي بتاريخ 24 سبتمبر 2025 بخصوص مشروع مشترك مزعوم واتفاقية ترخيص مع Art-Islets Pte. Ltd. وAustrianova. وأوضحت الشركة أن لم يتم تنفيذ أي اتفاق ملزم بين الطرفين في الوقت الحالي.
اعترفت الشركة بأن البيان السابق يحتوي على تصريحات صدرت عن خطأ وأكدت أن أي وصف لأنشطة تعاونية أو مساهمات تكنولوجية أو معالم تطوير سريري متوقعة من البيان المُسحوب لا يجب الاعتماد عليها. Avant Technologies تعرب عن أسفها لأي لبس حدث وتؤكد التزامها بتقديم معلومات دقيقة لأصحاب المصلحة.
Avant Technologies (OTCQB: AVAI) 已就其关于与 Art-Islets Pte. Ltd. 及 Austrianova 的涉嫌合资企业和许可协议的2025年9月24日新闻稿发布更正。公司澄清，目前双方尚未签署具有约束力的协议。
公司承认前一则公告中的部分陈述存在错误，并强调撤回公告中的任何关于合作活动、技术贡献或预计临床开发里程碑的描述都不应被依赖。Avant Technologies 对造成的任何混乱表示遗憾，并重申其为利益相关者提供准确信息的承诺。
- None.
- Retraction of previously announced joint venture agreement indicates poor internal controls
- Company issued misleading information to the public
- Potential damage to company's credibility and reputation
The September 24 release contained statements that were issued in error. No binding Joint Venture or License Agreement among Avant Technologies, Art-Islets, and Austrianova has been executed at this time. Accordingly, any descriptions of collaborative activities, technology contributions, or anticipated clinical development milestones contained in that release should not be relied upon.
Avant Technologies regrets the confusion caused by the earlier announcement and is committed to providing only accurate and verified information to its shareholders, partners, and the public.
For future updates and accurate Company information, please visit: https://avanttechnologies.com
Forward-Looking Statements
This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. Avant Technologies undertakes no obligation to revise or update such statements.
Contact:
Investor Relations
Avant Technologies, Inc.
Email: info@avanttechnologies.com
Logo - https://mma.prnewswire.com/media/2370694/5528268/Avant_Technologies.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-inc-issues-retraction-of-september-24-2025-press-release-302566054.html
SOURCE Avant Technologies Inc.
FAQ
What did Avant Technologies (AVAI) retract in their September 24, 2025 announcement?
Why did Avant Technologies (AVAI) issue the retraction?
How does the retraction affect Avant Technologies' (AVAI) partnership status?
What steps is Avant Technologies (AVAI) taking to address the situation?
Where can investors find accurate information about Avant Technologies (AVAI)?
